{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T11:29:29Z","timestamp":1782473369491,"version":"3.54.5"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T00:00:00Z","timestamp":1766620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG034924"],"award-info":[{"award-number":["R01AG034924"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG070926"],"award-info":[{"award-number":["R01AG070926"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["P30AG066508"],"award-info":[{"award-number":["P30AG066508"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","award":["16257"],"award-info":[{"award-number":["16257"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-67731-3","type":"journal-article","created":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T01:43:08Z","timestamp":1766626988000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["mGluR4\u2013NPDC1 complex mediates \u03b1-synuclein fibril-induced neurodegeneration"],"prefix":"10.1038","volume":"17","author":[{"given":"Azucena","family":"Perez-Canamas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9702-103X","authenticated-orcid":false,"given":"Mingming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leire","family":"Almandoz-Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabab","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si Jie","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allyson","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik C.","family":"Gunther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8188-3092","authenticated-orcid":false,"given":"Stephen M.","family":"Strittmatter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,25]]},"reference":[{"key":"67731_CR1","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini, M. G. et al. Alpha-synuclein in Lewy bodies. Nature 388, 839\u2013840 (1997).","journal-title":"Nature"},{"key":"67731_CR2","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1073\/pnas.95.11.6469","volume":"95","author":"MG Spillantini","year":"1998","unstructured":"Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M. & Goedert, M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson\u2019s disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. USA 95, 6469\u20136473 (1998).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"67731_CR3","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/j.parkreldis.2017.07.033","volume":"46","author":"DW Dickson","year":"2018","unstructured":"Dickson, D. W. Neuropathology of Parkinson disease. Parkinsonism Relat. Disord. 46, S30\u2013S33 (2018).","journal-title":"Parkinsonism Relat. Disord."},{"key":"67731_CR4","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.3233\/JPD-179005","volume":"7","author":"M Goedert","year":"2017","unstructured":"Goedert, M., Jakes, R. & Spillantini, M. G. The Synucleinopathies: twenty Years On. J. Parkinsons Dis. 7, S51\u2013S69 (2017).","journal-title":"J. Parkinsons Dis."},{"key":"67731_CR5","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1126\/science.1227157","volume":"338","author":"KC Luk","year":"2012","unstructured":"Luk, K. C. et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338, 949\u2013953 (2012).","journal-title":"Science"},{"key":"67731_CR6","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41586-018-0104-4","volume":"557","author":"C Peng","year":"2018","unstructured":"Peng, C. et al. Cellular milieu imparts distinct pathological alpha-synuclein strains in alpha-synucleinopathies. Nature 557, 558\u2013563 (2018).","journal-title":"Nature"},{"key":"67731_CR7","doi-asserted-by":"publisher","first-page":"E5308","DOI":"10.1073\/pnas.1514475112","volume":"112","author":"SB Prusiner","year":"2015","unstructured":"Prusiner, S. B. et al. Evidence for alpha-synuclein prions causing multiple system atrophy in humans with Parkinsonism. Proc. Natl. Acad. Sci. USA 112, E5308\u2013E5317 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"67731_CR8","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1093\/brain\/awt037","volume":"136","author":"M Masuda-Suzukake","year":"2013","unstructured":"Masuda-Suzukake, M. et al. Prion-like spreading of pathological alpha-synuclein in brain. Brain 136, 1128\u20131138 (2013).","journal-title":"Brain"},{"key":"67731_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2022.167930","volume":"435","author":"S Neupane","year":"2023","unstructured":"Neupane, S., De Cecco, E. & Aguzzi, A. The hidden cell-to-cell trail of alpha-synuclein aggregates. J. Mol. Biol. 435, 167930 (2023).","journal-title":"J. Mol. Biol."},{"key":"67731_CR10","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1016\/j.neuron.2024.06.029","volume":"112","author":"H Scheiblich","year":"2024","unstructured":"Scheiblich, H. et al. Microglia rescue neurons from aggregate-induced neuronal dysfunction and death through tunneling nanotubes. Neuron 112, 3106\u20133125 e3108 (2024).","journal-title":"Neuron"},{"key":"67731_CR11","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/s41593-019-0457-5","volume":"22","author":"MX Henderson","year":"2019","unstructured":"Henderson, M. X. et al. Spread of alpha-synuclein pathology through the brain connectome is modulated by selective vulnerability and predicted by network analysis. Nat. Neurosci. 22, 1248\u20131257 (2019).","journal-title":"Nat. Neurosci."},{"key":"67731_CR12","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/nature07761","volume":"457","author":"J Lauren","year":"2009","unstructured":"Lauren, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W. & Strittmatter, S. M. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457, 1128\u20131132 (2009).","journal-title":"Nature"},{"key":"67731_CR13","unstructured":"Mao, X. et al. Pathological alpha-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science 353 (2016)."},{"key":"67731_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2021.656426","volume":"15","author":"H Gu","year":"2021","unstructured":"Gu, H. et al. Lymphocyte activation gene 3 (Lag3) contributes to alpha-synucleinopathy in alpha-synuclein transgenic mice. Front. Cell Neurosci. 15, 656426 (2021).","journal-title":"Front. Cell Neurosci."},{"key":"67731_CR15","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114745","volume":"13","author":"M Emmenegger","year":"2021","unstructured":"Emmenegger, M. et al. LAG3 is not expressed in human and murine neurons and does not modulate alpha-synucleinopathies. EMBO Mol. Med. 13, e14745 (2021).","journal-title":"EMBO Mol. Med."},{"key":"67731_CR16","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1038\/nn.4648","volume":"20","author":"DG Ferreira","year":"2017","unstructured":"Ferreira, D. G. et al. alpha-synuclein interacts with PrP(C) to induce cognitive impairment through mGluR5 and NMDAR2B. Nat. Neurosci. 20, 1569\u20131579 (2017).","journal-title":"Nat. Neurosci."},{"key":"67731_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/mds.28774","volume":"37","author":"T Thom","year":"2022","unstructured":"Thom, T. et al. Cellular prion protein mediates alpha-synuclein uptake, localization, and toxicity in vitro and in vivo. Mov. Disord. 37, 39\u201351 (2022).","journal-title":"Mov. Disord."},{"key":"67731_CR18","doi-asserted-by":"publisher","first-page":"e1012517","DOI":"10.1371\/journal.ppat.1012517","volume":"20","author":"RWL So","year":"2024","unstructured":"So, R. W. L. et al. alpha-Synuclein strain propagation is independent of cellular prion protein expression in a transgenic synucleinopathy mouse model. PLoS Pathog. 20, e1012517 (2024).","journal-title":"PLoS Pathog."},{"key":"67731_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/science.abk0637","volume":"377","author":"ME Diaz-Ortiz","year":"2022","unstructured":"Diaz-Ortiz, M. E. et al. GPNMB confers risk for Parkinson\u2019s disease through interaction with alpha-synuclein. Science 377, eabk0637 (2022).","journal-title":"Science"},{"key":"67731_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2021.105494","volume":"159","author":"R Brendza","year":"2021","unstructured":"Brendza, R. et al. Genetic ablation of Gpnmb does not alter synuclein-related pathology. Neurobiol. Dis. 159, 105494 (2021).","journal-title":"Neurobiol. Dis."},{"key":"67731_CR21","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.nbd.2015.08.025","volume":"83","author":"YR Choi","year":"2015","unstructured":"Choi, Y. R. et al. FcgammaRIIB mediates the inhibitory effect of aggregated alpha-synuclein on microglial phagocytosis. Neurobiol. Dis. 83, 90\u201399 (2015).","journal-title":"Neurobiol. Dis."},{"key":"67731_CR22","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.celrep.2017.12.009","volume":"22","author":"YR Choi","year":"2018","unstructured":"Choi, Y. R. et al. Prion-like propagation of alpha-synuclein is regulated by the FcgammaRIIB-SHP-1\/2 signaling pathway in neurons. Cell Rep. 22, 136\u2013148 (2018).","journal-title":"Cell Rep."},{"key":"67731_CR23","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1126\/science.adp3645","volume":"387","author":"KM Wu","year":"2025","unstructured":"Wu, K. M. et al. Neuronal FAM171A2 mediates alpha-synuclein fibril uptake and drives Parkinson\u2019s disease. Science 387, 892\u2013900 (2025).","journal-title":"Science"},{"key":"67731_CR24","doi-asserted-by":"publisher","first-page":"105696","DOI":"10.1016\/j.nbd.2022.105696","volume":"168","author":"R Domingues","year":"2022","unstructured":"Domingues, R. et al. Extracellular alpha-synuclein: sensors, receptors, and responses. Neurobiol. Dis. 168, 105696 (2022).","journal-title":"Neurobiol. Dis."},{"key":"67731_CR25","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41586-023-06812-z","volume":"624","author":"Z Yao","year":"2023","unstructured":"Yao, Z. et al. A high-resolution transcriptomic and spatial atlas of cell types in the whole mouse brain. Nature 624, 317\u2013332 (2023).","journal-title":"Nature"},{"key":"67731_CR26","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1074\/mcp.RA119.001889","volume":"19","author":"E Griesser","year":"2020","unstructured":"Griesser, E. et al. Quantitative profiling of the human substantia nigra proteome from laser-capture microdissected FFPE tissue. Mol. Cell Proteom. 19, 839\u2013851 (2020).","journal-title":"Mol. Cell Proteom."},{"key":"67731_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109027","volume":"210","author":"MA Cenci","year":"2022","unstructured":"Cenci, M. A., Skovgard, K. & Odin, P. Non-dopaminergic approaches to the treatment of motor complications in Parkinson\u2019s disease. Neuropharmacology 210, 109027 (2022).","journal-title":"Neuropharmacology"},{"key":"67731_CR28","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/mds.28970","volume":"37","author":"O Rascol","year":"2022","unstructured":"Rascol, O., Medori, R., Baayen, C., Such, P., Meulien, D. & Group AS. A randomized, double-blind, controlled phase II study of Foliglurax in Parkinson\u2019s disease. Mov. Disord. 37, 1088\u20131093 (2022).","journal-title":"Mov. Disord."},{"key":"67731_CR29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1146\/annurev.pharmtox.37.1.205","volume":"37","author":"PJ Conn","year":"1997","unstructured":"Conn, P. J. & Pin, J. P. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharm. Toxicol. 37, 205\u2013237 (1997).","journal-title":"Annu. Rev. Pharm. Toxicol."},{"key":"67731_CR30","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/363274a0","volume":"363","author":"BR Conklin","year":"1993","unstructured":"Conklin, B. R., Farfel, Z., Lustig, K. D., Julius, D. & Bourne, H. R. Substitution of three amino acids switches receptor specificity of Gq alpha to that of Gi alpha. Nature 363, 274\u2013276 (1993).","journal-title":"Nature"},{"key":"67731_CR31","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1073\/pnas.92.5.1560","volume":"92","author":"E Galiana","year":"1995","unstructured":"Galiana, E., Vernier, P., Dupont, E., Evrard, C. & Rouget, P. Identification of a neural-specific cDNA, NPDC-1, able to down-regulate cell proliferation and to suppress transformation. Proc. Natl. Acad. Sci. USA 92, 1560\u20131564 (1995).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"67731_CR32","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1002\/jnr.20405","volume":"79","author":"C Evrard","year":"2005","unstructured":"Evrard, C. & Rouget, P. Subcellular localization of neural-specific NPDC-1 protein. J. Neurosci. Res. 79, 747\u2013755 (2005).","journal-title":"J. Neurosci. Res."},{"key":"67731_CR33","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1038\/nn1763","volume":"9","author":"S Kim","year":"2006","unstructured":"Kim, S. et al. NGL family PSD-95-interacting adhesion molecules regulate excitatory synapse formation. Nat. Neurosci. 9, 1294\u20131301 (2006).","journal-title":"Nat. Neurosci."},{"key":"67731_CR34","doi-asserted-by":"publisher","first-page":"6364","DOI":"10.1523\/JNEUROSCI.16-20-06364.1996","volume":"16","author":"R Pekhletski","year":"1996","unstructured":"Pekhletski, R. et al. Impaired cerebellar synaptic plasticity and motor performance in mice lacking the mGluR4 subtype of metabotropic glutamate receptor. J. Neurosci. 16, 6364\u20136373 (1996).","journal-title":"J. Neurosci."},{"key":"67731_CR35","doi-asserted-by":"publisher","first-page":"8968","DOI":"10.1073\/pnas.132197599","volume":"99","author":"MK Lee","year":"2002","unstructured":"Lee, M. K. et al. Human alpha-synuclein-harboring familial Parkinson\u2019s disease-linked Ala-53 -> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc. Natl. Acad. Sci. USA 99, 8968\u20138973 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"67731_CR36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1523\/JNEUROSCI.4308-05.2006","volume":"26","author":"LJ Martin","year":"2006","unstructured":"Martin, L. J. et al. Parkinson\u2019s disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J. Neurosci. 26, 41\u201350 (2006).","journal-title":"J. Neurosci."},{"key":"67731_CR37","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.gene.2004.08.020","volume":"343","author":"C Evrard","year":"2004","unstructured":"Evrard, C., Caron, S. & Rouget, P. Functional analysis of the NPDC-1 gene. Gene 343, 153\u2013163 (2004).","journal-title":"Gene"},{"key":"67731_CR38","doi-asserted-by":"publisher","first-page":"1255555","DOI":"10.1126\/science.1255555","volume":"349","author":"M Goedert","year":"2015","unstructured":"Goedert, M. NEURODEGENERATION. Alzheimer\u2019s and Parkinson\u2019s diseases: the prion concept in relation to assembled Abeta, tau, and alpha-synuclein. Science 349, 1255555 (2015).","journal-title":"Science"},{"key":"67731_CR39","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1523\/JNEUROSCI.5601-11.2012","volume":"32","author":"MS Moehle","year":"2012","unstructured":"Moehle, M. S. et al. LRRK2 inhibition attenuates microglial inflammatory responses. J. Neurosci. 32, 1602\u20131611 (2012).","journal-title":"J. Neurosci."},{"key":"67731_CR40","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1080\/13543784.2020.1839047","volume":"29","author":"D Doller","year":"2020","unstructured":"Doller, D., Bespalov, A., Miller, R., Pietraszek, M. & Kalinichev, M. A case study of foliglurax, the first clinical mGluR4 PAM for symptomatic treatment of Parkinson\u2019s disease: translational gaps or a failing industry innovation model?. Expert Opin. Investig. Drugs 29, 1323\u20131338 (2020).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"67731_CR41","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1002\/mds.27462","volume":"33","author":"D Charvin","year":"2018","unstructured":"Charvin, D. et al. An mGlu4-positive allosteric modulator alleviates parkinsonism in primates. Mov. Disord. 33, 1619\u20131631 (2018).","journal-title":"Mov. Disord."},{"key":"67731_CR42","doi-asserted-by":"publisher","first-page":"13668","DOI":"10.1073\/pnas.1835724100","volume":"100","author":"MJ Marino","year":"2003","unstructured":"Marino, M. J. et al. Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson\u2019s disease treatment. Proc. Natl. Acad. Sci. USA 100, 13668\u201313673 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"67731_CR43","doi-asserted-by":"publisher","first-page":"3619","DOI":"10.1096\/fj.09-131789","volume":"23","author":"C Beurrier","year":"2009","unstructured":"Beurrier, C. et al. Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism. FASEB J. 23, 3619\u20133628 (2009).","journal-title":"FASEB J."},{"key":"67731_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5501","volume":"5","author":"NH Tomioka","year":"2014","unstructured":"Tomioka, N. H. et al. Elfn1 recruits presynaptic mGluR7 in trans and its loss results in seizures. Nat. Commun. 5, 4501 (2014).","journal-title":"Nat. Commun."},{"key":"67731_CR45","doi-asserted-by":"publisher","first-page":"5022","DOI":"10.1073\/pnas.1722498115","volume":"115","author":"HA Dunn","year":"2018","unstructured":"Dunn, H. A., Patil, D. N., Cao, Y., Orlandi, C. & Martemyanov, K. A. Synaptic adhesion protein ELFN1 is a selective allosteric modulator of group III metabotropic glutamate receptors in trans. Proc. Natl. Acad. Sci. USA 115, 5022\u20135027 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"67731_CR46","doi-asserted-by":"publisher","unstructured":"Leonard H. L., Global Parkinson\u2019s Genetics P. Novel Parkinson\u2019s disease genetic risk factors within and across european populations. medRxiv, https:\/\/doi.org\/10.1101\/2025.1103.1114.24319455 (2025).","DOI":"10.1101\/2025.1103.1114.24319455"},{"key":"67731_CR47","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.neuroscience.2024.06.013","volume":"578","author":"K Belkacemi","year":"2025","unstructured":"Belkacemi, K., Rondard, P., Pin, J. P. & Prezeau, L. Heterodimers revolutionize the field of metabotropic glutamate receptors. Neuroscience 578, 46\u201358 (2025).","journal-title":"Neuroscience"},{"key":"67731_CR48","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1038\/nprot.2014.143","volume":"9","author":"LA Volpicelli-Daley","year":"2014","unstructured":"Volpicelli-Daley, L. A., Luk, K. C. & Lee, V. M. Addition of exogenous alpha-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous alpha-synuclein to Lewy body and Lewy neurite-like aggregates. Nat. Protoc. 9, 2135\u20132146 (2014).","journal-title":"Nat. Protoc."},{"key":"67731_CR49","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.neuron.2010.09.034","volume":"68","author":"F Hu","year":"2010","unstructured":"Hu, F. et al. Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin. Neuron 68, 654\u2013667 (2010).","journal-title":"Neuron"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67731-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67731-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67731-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T10:04:12Z","timestamp":1769508252000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67731-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,25]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["67731"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-67731-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,25]]},"assertion":[{"value":"6 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"994"}}